Colleges
Jack Tan
DPhil, BSc (Hons)
RDM Principal Investigator
Dr Tan is a Principal Investigator at the MRC Translational Immune Discovery Unit.
His research focuses developing next-generation protein nanoparticle-based vaccines and antibody therapeutics against infectious diseases. He is particularly interested in understanding how the architecture of protein nanoparticle vaccines influences their immunogenicity, as well as investigating mucosal vaccine immunity to improve vaccine design against respiratory pathogens such as coronavirus.
Dr Tan is part of an international consortium (Oxford-Caltech-CPI-Ingenza) funded by the Coalition of Epidemics Preparedness Innovations (CEPI) to develop novel a pan-sarbecovirus (SARS-like betacoronavirus) nanoparticle vaccine. He is also a Career Development Fellow at the Chinese-Academy of Medical Sciences-Oxford Institute, and a Fellow by Special Election at St Edmund Hall.
Key publications
-
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Journal article
Tan TK. et al, (2021), Nat Commun, 12
Recent publications
-
Publisher Correction: The molecular reach of antibodies crucially underpins their viral neutralisation capacity.
Journal article
Huhn A. et al, (2025), Nat Commun, 16
-
A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
Journal article
Sadler HL. et al, (2025), J Virol
-
The molecular reach of antibodies crucially underpins their viral neutralisation capacity.
Journal article
Huhn A. et al, (2025), Nat Commun, 16
-
Development of a recombinant non-replicating Newcastle disease virus.
Journal article
Cheow P-S. et al, (2024), Avian Pathol, 1 - 9
-
Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses.
Journal article
Hills RA. et al, (2024), Nat Nanotechnol
-
Single-cycle influenza virus vaccine generates lung CD8+ Trm that cross-react against viral variants and subvert virus escape mutants.
Journal article
Zheng MZM. et al, (2023), Sci Adv, 9
-
The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency
Preprint
Huhn A. et al, (2023)
-
Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents.
Journal article
Gelinas AD. et al, (2023), Mol Ther Nucleic Acids, 31, 370 - 382
-
Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology.
Journal article
Hills RA. et al, (2023), bioRxiv
-
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
Journal article
Huang K-YA. et al, (2023), Nat Commun, 14
-
Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors.
Journal article
Kandasamy M. et al, (2023), Elife, 12
-
The magnitude and cross reactivity of SARS-CoV-2 specific antibody responses in vaccinated and unvaccinated Sri Lankan children and association with nutrition status
Preprint
Jeewandara C. et al, (2023)
-
Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.
Journal article
Zheng MZM. et al, (2022), J Immunol, 209, 1832 - 1836
-
Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.
Journal article
Zheng MZM. et al, (2022), J Immunol
-
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.
Journal article
Cohen AA. et al, (2022), Science, 377
-
Pathogen-sugar interactions revealed by universal saturation transfer analysis.
Journal article
Buchanan CJ. et al, (2022), Science, 377
-
SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly.
Journal article
Vester SK. et al, (2022), Nat Commun, 13
-
Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.
Journal article
Jeewandara C. et al, (2022), Immunology
-
Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222.
Journal article
Jayathilaka D. et al, (2022), Clin Exp Immunol, 208, 323 - 331
-
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.
Journal article
Jeewandara C. et al, (2022), Immun Inflamm Dis, 10